• PExA highlighted new research using its non-invasive biomarker collection technology at the ERS lung congress in Barcelona in early September.
• Study results were already presented, with three accepted abstracts shown during the meeting.
• The studies supported the technology’s potential to enable broader clinical and drug-development work in lung diseases, including future diagnostic use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PExA AB published the original content used to generate this news brief via Cision (Ref. ID: 202609290415BITN____UKPR__SV_20260929-BIT-6552-0) on September 29, 2026, and is solely responsible for the information contained therein.